

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 7/02, 7/00	A1	(11) International Publication Number: WO 98/26048 (43) International Publication Date: 18 June 1998 (18.06.98)
(21) International Application Number: PCT/US97/22134 (22) International Filing Date: 11 December 1997 (11.12.97) (30) Priority Data: 08/766,835 13 December 1996 (13.12.96) US (71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US). (72) Inventors: TANG, John, Chu-Tay; 19 Camelot Drive, Livingston, NJ 07039 (US). VELLEKAMP, Gary, J.; 10 Clinton Road, Glen Ridge, NJ 07028 (US). BONDOC, Laureano, L., Jr.; 210 St. Marks Avenue, Piscataway, NJ 08854 (US). (74) Agents: GOULD, James, M. et al.; Schering-Plough Corporation, Patent Dept., K-6-1, 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU. ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW). Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM). European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: METHODS FOR PURIFYING VIRUSES (57) Abstract The invention provides methods for purifying a virus from impurities in an aqueous medium.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHODS FOR PURIFYING VIRUSES

5 BACKGROUND OF THE INVENTION

The cultivation and purification of viruses has become increasingly important for gene therapy and vaccine development. Huyghe et al. (Human Gene Therapy 6: 1403-1416 (1995)) disclosed a comparison of several methods for purification of recombinant adenoviruses, including anion-exchange chromatography, size exclusion chromatography, immobilized zinc affinity chromatography, ultracentrifugation, concluding that the preferred process for purification of a recombinant adenovirus is nuclease treatment of a cell lysate, followed by filtration through membrane filters, followed by DEAE chromatography, followed by zinc affinity chromatography.

15 In view of the ever-increasing need for purified viruses, for example for use as viral vectors for gene therapy, improved methods of purification would be highly desired.

SUMMARY OF THE INVENTION

20 One aspect of the invention is a method for purification of a virus preparation comprising:

- a) subjecting the virus preparation to anion-exchange chromatography, wherein the virus is eluted from an anion-exchange chromatographic medium; and
- 25 b) subjecting the virus product of step a to size exclusion chromatography, wherein the virus is eluted from a size exclusion chromatographic medium. The virus preparation can be a cell lysate, which can be filtered before step A. The virus can be recombinant adenovirus, such as ACN53 (disclosed in WO 95/11984).

30 The anion exchange medium can comprise diethylaminoethyl groups on a cross-linked agarose, cellulose, polyacrylamide or polystyrene backbone, such as FRACTOGEL™-DEAE. The size-exclusion medium can comprise a cross-linked polysaccharide, and may be a composite of cross-linked agarose and dextran. An exemplary size exclusion medium is Superdex-200.

35 The anion exchange chromatographic medium can be extensively washed before application of the virus preparation.

The size-exclusion medium can be provided in a column prepared as a salt gradient decreasing in ionic strength from the top of the column towards

the bottom, the top of the column having a buffer having an ionic strength substantially identical to that of the product of step a.

A further aspect of the invention is a virus purified by the method of claim 1.

5

DESCRIPTION OF THE PREFERRED EMBODIMENT

The present invention relates to the purification of a virus, which may for example have been produced by cultivation in a cellular host and then liberated by lysis of the cells and separation from cellular debris. The term "virus" includes wild type, mutant, and recombinant viruses, especially adenoviral vectors for expression of heterologous nucleic acid sequences.

10

The embodiments of the invention fall into the general strategy of adsorption chromatography of a virus preparation followed by size exclusion chromatography. Typically the anion exchange chromatography is carried out on an anion-exchange resin consisting of basic groups in side chains attached to a macromolecular backbone. The basic groups are preferably substituted amino groups, in particular diloweralkylaminoalkyl groups where each lower alkyl group has 1 to 4, preferably 2, carbon atoms, and each alkyl group has 2 to 4, preferably 2, carbon atoms. The backbone can be composed of silica or an organic matrix, for example cross-linked agarose, cellulose, polyacrylamide or polystyrene; it is particularly preferred to use an anion exchange resin consisting of dimethylaminoethyl groups (DMAE groups) or especially of diethylaminoethyl groups (DEAE groups) on a cross-linked agarose backbone; especially preferred resins of the DEAE type are those sold under the trade name "DEAE-Fractogel", e.g., "FRACTOGEL™ EMD DEAE-650M", and "FRACTOGEL™ AE. In some embodiments of the invention, the "backbone" can be a solid support such as a bead.

15

20

25

The anion-exchange-resin is preferably washed extensively before loading the virus preparation to remove preservatives such as sodium azide and ethanol, and other extraneous materials, by washing the column with about 5 to 10 column volumes of a basic solution such as 50 mM NaOH/1 M NaCl, followed by about 5 to 10 column volumes of a neutralizing solution such as 50 mM HCl/1 M NaCl, followed by about 5 to 30 volumes of loading and/or elution buffers. Optionally, the column is washed with a buffer of lower salt concentration than the loading and/or elution buffer before washing with loading and/or elution buffer.

30

35

Typically, a preparation of virus such as a cell lysate is loaded onto the chromatographic medium in a buffered solution of about pH 7.0 - 8.5, with a salt concentration of about 100-360 mM. The salt is typically NaCl. In some

embodiments other buffers such as phosphate or Tris are used. Contaminants can be preferentially eluted by washing the column with a buffer at a salt concentration of about 250-380 mM. The virus can then be eluted by a solution with a salt concentration of about 360-600 mM. The salt is typically NaCl.

- 5 Typically, about 5 to 50, more preferably about 30 volumes of buffer are used to elute the virus. Fractions may be collected and assayed for the presence of virus by measuring the A_{260} or A_{280} and pooling peak fractions; alternatively, the eluant containing the A_{260} or A_{280} peak may be collected in a single fraction. This single A_{260} or A_{280} fraction or pooled fractions in the eluant containing the
- 10 virus are termed "anion-exchange pool" herein.

- In the size-exclusion chromatography step, molecules are separated according to size in a bed packed with an inert porous medium, especially an inert gel medium, which is preferably a composite of cross-linked polysaccharides, e.g., cross-linked agarose and dextran in the form of spherical
- 15 beads. Molecules larger than the largest pores in the swollen gel beads do not enter the gel beads and therefore move through the chromatographic bed fastest. Smaller molecules, which enter the gel beads to varying extent depending on their size and shape, are retarded in their passage through the bed. Molecules are thus generally eluted in the order of decreasing molecular size. Viruses,
- 20 because of their large size, generally elute in the void volume. For example, adenoviruses have a diameter of approximately 80 nm. Media appropriate for size-exclusion chromatography of adenoviruses include but are not limited to such resins as G6000PWXL (TosoHaas); SB-806 (Alltech); Sephacryl S-400 HR, Sephacryl S-500 HR, Sephacryl S-1000 SF, Sephadex G-200, Sepharose CL-
- 25 2B; Superdex 200 prep grade, Superose 6 prep grade (Pharmacia); TSK 6000PWXL (Bodman), and Ultrahydrogel 2000 (Waters).

- "Size-exclusion" chromatography as used herein is intended to include gel filtration chromatography. A particularly preferred size-exclusion medium is that sold under the trade name "Superdex 200"; see the Pharmacia Catalog, 1996,
- 30 pages 338-339, code no. 17-1043-01 (bulk), or 17-1069-01 or 17-1071-01 (pre-packed columns). Since a group separation of virus from impurities of lower molecular weight is achieved, the loading volume of starting materials from the anion-exchange pool can be relatively large, e.g., up to 20%, more preferably 15%, of the bed volume.

- 35 Exemplary materials for the practice of the anion-exchange and size exclusion chromatographic steps of the invention are provided in Table I. Exemplary variables and controls are provided in Tables II and III.

Table I: Exemplary Materials Used In Anion-Exchange and Size Exclusion Chromatography

Purification Step	Procedure	Solution Used
DEAE-Fractogel	Salt Adjustment	4 M NaCl
	Equilibration	265 mM NaCl, 2 mM MgCl ₂ , 2% (w/v) sucrose, 50 mM sodium phosphate at pH 7.5 (Buffer A)
		50 mM NaOH, 1M NaCl
		100 mM HCl, 1M NaCl
	Wash 1	265 mM NaCl, 2 mM MgCl ₂ , 2% (w/v) sucrose, 50 mM sodium phosphate at pH 7.5 (Buffer A)
	Wash 2	265 mM NaCl, 2 mM MgCl ₂ , 2% (w/v) sucrose, 50 mM sodium phosphate at pH 7.5 (Buffer A)
		600 mM NaCl, 2 mM MgCl ₂ , 2% (w/v) sucrose, 50 mM sodium phosphate at pH 7.5 (Buffer B)
	Elution	265 mM NaCl, 2 mM MgCl ₂ , 2% (w/v) sucrose, 50 mM sodium phosphate at pH 7.5 (Buffer A)
		600 mM NaCl, 2 mM MgCl ₂ , 2% (w/v) sucrose, 50 mM sodium phosphate at pH 7.5 (Buffer B)
Superdex 200	Equilibration	130 mM NaCl, 2 mM MgCl ₂ , 2% (w/v) sucrose, 50 mM sodium phosphate at pH 7.5 (Buffer C)
	Elution	130 mM NaCl, 2 mM MgCl ₂ , 2% (w/v) sucrose, 50 mM sodium phosphate at pH 7.5 (Buffer C)

Table II: In-process Control and Operating Variables for the Anion-Exchange Chromatography

5

Purification Procedure	Variable	Recommended Value
All procedures	Temperature	4-12°C
Equilibration 1) NaOH/NaCl 2) HCl/NaCl 3) Buffer A	Flow rate	< 5 cm/min.
	Volume	5 column volumes
	pH of effluent	12.0
	Volume	6 column volumes
	pH of effluent	8.0
	Volume	10 column volumes
Load	pH of effluent	equivalent to Buffer A ± 0.2 pH
	Flow rate	<5 cm/min
	Conductivity of the feed	20-30 mS

Wash 1:	Buffer A	Flow rate Volume	<5 cm/min 4 column volumes
Wash 2:	Buffer A/ Buffer B	Flow rate Volume	<5 cm/min 8 column volumes
Elution:	Buffer A/ Buffer B	Flow rate Volume	< 5 cm/min 30 column volumes
Fraction Selection	A ₂₈₀		>>background

Table III: In-Process Control and Operating Variables for the Size-Exclusion Chromatography

Purification Procedure	Variable	Recommended Value
All procedures	Temperature	4-12°C
Equilibration: Buffer C	Flow rate Volume pH of Effluent	<1 cm/min 1 column volume equivalent to Buffer C \pm 0.2 pH
Load	Flow Rate Volume Concentration	<1 cm/min 0.2 column volumes 30 A ₂₈₀ /mL
Elution: Buffer C:	Flow rate Volume	<1 cm/min 1 column volume
Fraction Selection	A ₂₈₀	>>background

5 In an embodiment of the invention, the virus is loaded from the anion-exchange pool onto a size-exclusion column. In some embodiments, the column is prepared with a salt gradient decreasing in ionic strength from the top towards the bottom of the column. After loading, the virus moves down through the salt gradient (since the virus is preferentially not adsorbed by the resin) and

10 the gentle change in ionic strength avoids damage to the virus. After overtaking the salt gradient, the virus is eluted in a low-salt (e.g. 0-200 mM NaCl) buffer. Such low salt buffers include, but are not limited to, formulations for long term storage or administration to patients.

15 In some embodiments, glycerol is added to the chromatographic buffers, such as elution buffer, or to the pooled fractions containing virus. Typically the glycerol is present in a final concentration of 5-20%, more typically 10%. Thus, in some embodiments, glycerol is present in all solutions throughout the process. In further embodiments, other excipients, such as about 2-16% sucrose, may be used in place of the glycerol.

In a preferred embodiment, the size exclusion chromatography column is equilibrated with buffer at low salt concentration, e.g., about 100 to 150 mM, especially about 130 mM NaCl. Just prior to loading the feed, a salt gradient is loaded, equivalent to a moderate fraction of the bed volume, e.g. 10 to 20%, preferably about 15%, from low salt concentration (about 130 mM NaCl) to the higher salt concentration of the feed (e.g., 400 to 450 mM NaCl, especially about 420 mM NaCl).

A simple test is performed to determine the quality of the DEAE-Fractogel pool and consequently whether a salt gradient should be used. This test depends on the constancy of the A_{320}/A_{260} ratio of the DEAE-Fractogel pool diluted with an appropriate pH 7.5 buffer over a period of a few minutes (e.g., 5 minutes). An appropriate buffer consists of 50 mM sodium phosphate, pH 7.5, 2 mM $MgCl_2$, 2% sucrose, no NaCl. If the A_{320}/A_{260} ratio remains substantially constant over a 5-minute period (e.g., if it increases by no more than 0.04), then that sample is suitable for either isocratic or salt-gradient size-exclusion chromatography. If the ratio of A_{320}/A_{260} increases more than about 0.04 during that period, then that DEAE-Fractogel pool is preferably performed on salt-gradient size-exclusion chromatography to improve the yield. Table IV provides exemplary materials and protocols for the use of salt gradient size exclusion chromatography.

Table IV. Exemplary materials and protocols for the use of salt gradient size exclusion chromatography.

Step	Procedure	Typical Range	Preferred values
Step (i)	Equilibrate the column with the low salt buffer	100 to 150 mM NaCl	130 mM NaCl
Step (ii)	Generate salt gradient at top of column	(100-150) to (400-500) mM NaCl; 10 to 20% bed volume	130 to 450 mM NaCl; 15% bed volume
Step (iii)	Load the DEAE-pool onto the column.	10 to 20% bed volume	15% bed volume
Step (iv)	Elute the adenovirus with high-salt solution	400 to 500 mM NaCl	450 mM NaCl
Step (v)	Complete the elution of the Virus.	400 to 500 mM NaCl	450 mM NaCl

The purification method of the present invention is suitable for scaling-up (or scaling down) and for large-scale containment. Suitable

procedures and guidelines well-known in the art can be used and followed to control the virus and prevent biohazardous situations: see, e.g., "Biosafety in Microbiological and Biomedical Laboratories", 3rd Edition, edited by Richman and McKinney, U.S. Department of Health and Human Services, published by the Center for Disease Control and the National Institute of Health, Washington, DC, U.S. Government Printing Office, May 1993.

The methods of the instant invention are amenable to a wide range of viruses, including but not limited to adenoviruses, pox viruses, iridoviruses, herpes viruses, papovaviruses, paramyxoviruses, orthomyxoviruses, retroviruses, and rotaviruses. The viruses are preferably recombinant viruses, but can include clinical isolates, attenuated vaccine strains, and so on.

Thus, for example, an exemplary recombinant adenovirus is that can be purified by the method of the invention is ACN53, which is disclosed in PCT patent application no. WO 95/11984.

In the first step, the ACN53 adenoviral vector is purified by anion exchange chromatography on a DEAE-column. For this, the virus is typically propagated in 293 kidney cells, harvested, and subjected to concentration and ultrafiltration. The concentrate is frozen and stored at about -20°C until use. Frozen concentrate is thawed, clarified by filtration through a 0.45 µm filter, the conductivity of the preparation adjusted to about 250-360 mM NaCl, and subjected to DEAE chromatography. Solutions used in the chromatography are listed in Table 1.

In the second step, the ACN53 adenoviral vector is purified by size-exclusion chromatography on a Superdex-200 column. Selected fractions containing virus are identified by A₂₆₀ or A₂₈₀ and pooled. The pooled fractions constitute the purified bulk ACN53 adenoviral vector which is then filtered sterile through a 0.2 µm filter and stored at about -20°C.

The virus in the DEAE-Fractogel pool may be unstable due to the presence of a high concentration of salt (about 420 mM NaCl). It is preferably processed immediately or stored at 4-12°C for not more than about 24 hours.

Fractions of the elution profile showing the ACN53 adenoviral vector peak as determined by A₂₆₀ or A₂₈₀ are pooled for further processing. The size-exclusion pool is filtered through a 0.2 µm filter. This filtrate, the final purified bulk ACN53 adenoviral vector, is then transferred into sterile plastic bottles (e.g. Teflon) and stored at about -20°C. The in-process controls for this step are listed in Table III.

The increase in purity of the ACN53 adenoviral vector at each step of the purification method can be followed by Resource Q HPLC (see Huyghe et

al., Human Gene Therapy, Vol. 6 (November 1995), pp. 1403-1416 at p. 1405).

The quality of the virus in the first and second chromatographic pools is also monitored by spectroscopic methods. The characteristic ratio of A_{260}/A_{280} is 1.23-1.31:1 for final purified virus. The light scattering which results from the high molecular weight of the virus is derived from the ratio of A_{320}/A_{260} nm and is also used to monitor the chromatographic pools. Purified, free virus particles display a light scattering ratio of about 0.22-0.30:1.

The following Examples serve to illustrate the present invention. The selected vectors and hosts and other materials, the concentration of reagents, the temperatures, and the values of other variables are only to exemplify how the present invention may be carried out, and are not to be considered limitations thereof.

EXPERIMENTAL EXAMPLES

A. Small Scale Purification of Adenovirus

(1) Anion-Exchange Chromatography (DEAE-Fractogel)

A DEAE-EMD Fractogel 650M column (E. Merck), 5 x 18 cm., was pre-equilibrated with 5 bed volumes (B.V.) of 0.5 M NaOH / 1M NaCl followed by 6 B.V. of 0.1 M HCl / 1 M NaCl, and then by 20 B.V. of Buffer A (265 mM NaCl, 2 mM $MgCl_2$, 2% (w/v) sucrose, 50 mM sodium phosphate at pH 7.5) at a linear flow rate of 2 cm/min. The feed for this column was derived from 2 liters of frozen crude virus solution, which was thawed, microfiltered through a 0.45 μ membrane, and adjusted with a small volume of 4 M NaCl to a conductivity equal to that of Buffer A. The feed was loaded onto the column at a linear flow rate of 1 cm/min. The column was washed with 4 B.V. of Buffer A. The column was then washed with 8 B.V. of 94% Buffer A / 6% Buffer B (identical to Buffer A except that NaCl was 600 mM). The column was eluted with 30 B.V. of a linear gradient from 94% Buffer A / 6% Buffer B to 100% Buffer B. Fractions containing substantial virus were pooled to form the feed ("DEAE pool") for the following column.

(2) Isocratic Size-Exclusion Chromatography (Superdex-200)

Size exclusion chromatography was performed on a Superdex-200 column (Pharmacia), 5 x 73 cm, pre-equilibrated with 0.5 B.V. 0.5 M NaOH, 1 B.V. of H_2O , and 2 B.V. of Buffer C (130 mM NaCl, 2 mM $MgCl_2$, 2% (w/v) sucrose, 50 mM sodium phosphate at pH 7.5) at a linear flow rate of 0.6 cm/min. The feed consisting of 220 ml of DEAE pool was loaded onto the column. ACN53 was eluted with Buffer C at a linear flow rate of 0.6 cm/min. Fractions with substantial virus were pooled, passed through a 0.2 μ microfilter and stored. The virus

concentrate can be stored at low temperature, e.g., at 0–10°C, preferably at about 4°C, or if the volume is small, e.g., less than about 50 ml, frozen at –80°C.

(3) Salt-Gradient Size-Exclusion Chromatography

5 (a). Salt Dilution Test

The DEAE-Fractogel pool (0.4 ml) was mixed with of a buffer consisting of 50 mM sodium phosphate, pH 7.5, 2 mM MgCl_2 , 2% sucrose, no NaCl (0.8 ml) and immediately placed in a quartz cuvette and measured for absorbance at 260 and 320 nm on a UV spectrometer equipped with a photodiode array. Without removal of the sample from the cuvette, the reading was repeated at 1-2 minute intervals over a 5-minute period. If the ratio of A_{320}/A_{260} was substantially constant during that period, then that DEAE-Fractogel pool was suitable for either isocratic or salt-gradient size-exclusion chromatography. If the ratio of A_{320}/A_{260} increased more than about 4% during that period, then that DEAE-Fractogel pool required salt-gradient size-exclusion chromatography to improve the yield.

(b) Salt-Gradient Size-Exclusion Chromatography

A salt-gradient chromatography was performed on a Superdex-200 column, 2.6 cm x 60 cm, pre-equilibrated with 0.5 B.V. 0.5 M NaOH, 1 B.V. of H_2O , and 2 B.V. of Buffer C (20 mM sodium phosphate, pH 8.0, 130 mM NaCl, 2mM MgCl_2 , 2% sucrose). Immediately prior to loading the DEAE pool, a linear gradient from 100% Buffer C to 100% Buffer D (20 mM sodium phosphate, pH 8.0, 420 mM NaCl, 2 mM MgCl_2 , 2% sucrose) of 0.15 B.V. (48 ml) was applied to the Superdex-200 column. The feed consisting of 20 ml of a DEAE pool that had failed the above test was then loaded onto the column and eluted with Buffer D at a linear flow rate of 0.6 cm/min. Fractions with substantial virus eluting in or near the void volume were pooled, passed through a sterilizing filter and stored at –80°C. The step yield was 60% and the A_{320}/A_{260} ratio was 0.24:1.

30

B. Large-Scale Purification of Adenovirus

(1) Anion Exchange Chromatography

The frozen vial concentrate from the fermentation and recovery step was thawed and filtered through a 0.45 μm hydrophilic Durapore membrane in a Millipore 10" Opticap capsule. The filtrate was collected in a closed tank. To minimize losses, the filter cartridge was washed with about 1.5 L of buffer J-1 (50 mM sodium phosphate pH 7.5, 265 mM sodium chloride, 2 mM magnesium chloride, 2% (w/v) sucrose) supplemented with 5.4% (w/w) of solution J-3 (4 M

sodium chloride). The salt concentration of the filtrate was adjusted by adding 5.4% (w/v) of solution J-3 (4 M sodium chloride). This feed solution was then applied to a Fractogel EMD DEAE-650 M column (7 cm diameter, 14.8 cm bed height, 570 ml bed volume) pre-equilibrated with buffer J-1 (50 mM sodium phosphate pH 7.5, 265 mM sodium chloride, 2 mM magnesium chloride, 2% (w/v) sucrose). The Adenovirus binds to the anion exchange resin, whereas the majority of media and host cell impurities pass through the column in the spent charge. The column was initially washed with 4 bed volumes of buffer J-1 followed by a second isocratic wash of 8 bed volumes of 94% buffer J-1 and 6% buffer J-2 (50 mM sodium phosphate pH 7.5, 600 mM sodium chloride, 2 mM magnesium chloride, 2% (w/v) sucrose) to remove additional impurities. The virus was eluted from the column with a 30 bed volume linear gradient from 6% to 100% buffer J-2. The adenovirus peak of the elution profile as determined by A_{280} was collected and pooled for further processing. The in-process controls and operating parameters for the anion exchange chromatography step are summarized in Table V.

Table V: In-Process Control and Operating Parameters for the Anion-Exchange Chromatography

Column size: 7 cm diameter, 14.8 cm bed height, 570 ml bed volume		
Purification Procedure	Parameter	Value
All Procedures	Temperature	3 to 9 °C
Equilibration	Flow Rate	4 cm/min
	Volume	22 Column Volumes
	pH of Effluent	Equal to Buffer J-1 (7.4)
Load	Flow Rate	1 cm/min
	Conductivity of the Feed	28.2 mS
Wash 1	Flow Rate	2 cm/min
	Volume	4 Column Volumes
Wash 2	Flow Rate	2 cm/min
	Volume	8 Column Volumes
Elution	Flow Rate	2 cm/min
	Volume	30 Column Volumes
Fraction Selection	A_{280}	Peak area

(2) Size Exclusion Chromatography

The DEAE-Pool was applied immediately to a Superdex-200 size exclusion column (14 cm diameter, 77 cm bed height, 11.9 L bed volume) pre-equilibrated with buffer K-1 (20 mM sodium phosphate pH 8.0, 100 mM sodium chloride, 2 mM magnesium chloride, 2% (w/v) sucrose). The column was eluted with buffer K-1. The adenovirus peak of the elution profile as determined by A₂₈₀ was collected and pooled. This chromatography step achieved a buffer exchange and separation of low molecular weight impurities from the adenovirus product. The in-process controls and operating parameters for the size exclusion chromatography step are summarized in Table VI.

Table VI: In-Process Control and Operating Parameters for the Size Exclusion Chromatography

Column size: 14 cm diameter, 77 cm bed height, 11.9 L bed volume		
Purification Procedure	Parameter	Value
All Procedures	Temperature	3 to 9 °C
Equilibration	Flow Rate	0.43 cm/min
	Volume	2.3 Column Volume
Load	Flow Rate	0.43 cm/min
	Volume	≤0.09 Column Volumes
	Concentration	2.7 A ₂₈₀ /mL
Elution	Flow Rate	0.43 cm.min
	Volume	1.5 Column Volume
Fraction Selection	A ₂₈₀	Peak area

(3) Final 0.2 µm Filtration

The Superdex 200-pool was filtered through a 0.2 µm hydrophilic Durapore membrane (Stericup, Millipore) at 2 to 15°C. This step was carried out under sterile conditions in a biosafety cabinet. Because several filtration devices were used, the individual filtrates were pooled and then aliquoted into autoclaved containers. The containers of bulk drug substance in solution were frozen in a dry ice/ethanol bath and stored at about -20°C.

All publications and patent applications cited herein are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

Modifications and variations of this invention will be apparent to those skilled in the art. The specific embodiments described herein are offered by way of example only, and the invention is not to be construed as limited
5 thereby.

WHAT IS CLAIMED IS:

1. A method for purification of a virus preparation comprising:
 - a) subjecting the virus preparation to anion-exchange chromatography, wherein the virus is eluted from an anion-exchange chromatographic medium; and
 - b) subjecting the virus product of step A to size exclusion chromatography, wherein the virus is eluted from a size exclusion chromatographic medium.
2. The method of claim 1, wherein the virus preparation is a cell lysate.
3. The method of claim 2, wherein the cell lysate is filtered before step a.
4. The method of claim 1, wherein the virus is a recombinant adenovirus.
5. The method of claim 1, wherein the size-exclusion medium is provided in a column prepared as a salt gradient decreasing in ionic strength from the top of the column towards the bottom, the top of the column having a buffer having an ionic strength substantially identical to that of the product of step a.
6. The method of claim 1 wherein the virus is ACN53.
7. The method of claim 1, wherein the anion exchange chromatographic medium is extensively washed before application of the virus preparation.
8. A virus purified by the method of claim 1.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/22134

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N7/02 C12N7/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	EP 0 593 339 A (PASTEUR MERIEUX SERUMS VACC) 20 April 1994 see the whole document ---	1-8
X	EP 0 522 291 A (SCLAVO BIOGINE SPA) 13 January 1993 see the whole document ---	1-8
X	WO 95 11984 A (CANJI INC) 4 May 1995 cited in the application see the whole document -----	8

☐ Further documents are listed in the continuation of box C

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

5 March 1998

Date of mailing of the international search report

20.03.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx 31 551 eppo.nl
Fax (+31-70) 340-2016

Authorized officer

Hillenbrand, G

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/22134

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0593339 A	20-04-94	FR 2696748 A	15-04-94
		CA 2108292 A	15-04-94
		JP 6279317 A	04-10-94

EP 0522291 A	13-01-93	IT 1248075 B	05-01-95
		AT 156187 T	15-08-97
		DE 69221225 D	04-09-97
		JP 7177882 A	18-07-95
		US 5607851 A	04-03-97

WO 9511984 A	04-05-95	US 5591209 A	07-01-97
		AU 8125094 A	22-05-95
		BR 9407956 A	26-11-96
		CA 2173975 A	04-05-95
		CZ 9601143 A	13-11-96
		EP 0797676 A	01-10-97
		FI 961755 A	04-06-96
		JP 9507051 T	15-07-97
		NO 961639 A	24-06-96
		NZ 275956 A	22-09-97
		PL 314239 A	02-09-96
		SK 51096 A	01-10-96
		AU 2637295 A	18-12-95
		WO 9532020 A	30-11-95
		US 5534015 A	09-07-96
